69 related articles for article (PubMed ID: 12205566)
21. Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.
Wallace SJ; Li J; Nation RL; Prankerd RJ; Boyd BJ
J Pharm Sci; 2012 Sep; 101(9):3347-59. PubMed ID: 22623044
[TBL] [Abstract][Full Text] [Related]
22. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.
Ly NS; Yang J; Bulitta JB; Tsuji BT
Antimicrob Agents Chemother; 2012 Jun; 56(6):3453-6. PubMed ID: 22470116
[TBL] [Abstract][Full Text] [Related]
23. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.
Moskowitz SM; Brannon MK; Dasgupta N; Pier M; Sgambati N; Miller AK; Selgrade SE; Miller SI; Denton M; Conway SP; Johansen HK; Høiby N
Antimicrob Agents Chemother; 2012 Feb; 56(2):1019-30. PubMed ID: 22106224
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Sub-MIC β-Lactam Antibiotic Exposure of Pseudomonas aeruginosa Strains from People with Cystic Fibrosis in a Desiccation Survival Model.
Clifton IJ; Denton M; M'zali F; Peckham DG
Int J Microbiol; 2011; 2011():712618. PubMed ID: 21977035
[TBL] [Abstract][Full Text] [Related]
25. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.
Miller AK; Brannon MK; Stevens L; Johansen HK; Selgrade SE; Miller SI; Høiby N; Moskowitz SM
Antimicrob Agents Chemother; 2011 Dec; 55(12):5761-9. PubMed ID: 21968359
[TBL] [Abstract][Full Text] [Related]
26. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.
Lim LM; Ly N; Anderson D; Yang JC; Macander L; Jarkowski A; Forrest A; Bulitta JB; Tsuji BT
Pharmacotherapy; 2010 Dec; 30(12):1279-91. PubMed ID: 21114395
[TBL] [Abstract][Full Text] [Related]
27. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Moskowitz SM; Garber E; Chen Y; Clock SA; Tabibi S; Miller AK; Doctor M; Saiman L
J Antimicrob Chemother; 2010 Jul; 65(7):1416-23. PubMed ID: 20430789
[TBL] [Abstract][Full Text] [Related]
28. Current treatment of pseudomonal infections in the elderly.
Pappas G; Saplaoura K; Falagas ME
Drugs Aging; 2009; 26(5):363-79. PubMed ID: 19552489
[TBL] [Abstract][Full Text] [Related]
29. Segregation is good for patients with cystic fibrosis.
Conway S
J R Soc Med; 2008 Jul; 101 Suppl 1(Suppl 1):S31-5. PubMed ID: 18607016
[No Abstract] [Full Text] [Related]
30. A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis.
Clifton IJ; Fletcher LA; Beggs CB; Denton M; Peckham DG
BMC Microbiol; 2008 Jun; 8():105. PubMed ID: 18582388
[TBL] [Abstract][Full Text] [Related]
31. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa.
Mentzelopoulos SD; Pratikaki M; Platsouka E; Kraniotaki H; Zervakis D; Koutsoukou A; Nanas S; Paniara O; Roussos C; Giamarellos-Bourboulis E; Routsi C; Zakynthinos SG
Intensive Care Med; 2007 Sep; 33(9):1524-32. PubMed ID: 17549457
[TBL] [Abstract][Full Text] [Related]
32. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients.
Jelsbak L; Johansen HK; Frost AL; Thøgersen R; Thomsen LE; Ciofu O; Yang L; Haagensen JA; Høiby N; Molin S
Infect Immun; 2007 May; 75(5):2214-24. PubMed ID: 17261614
[TBL] [Abstract][Full Text] [Related]
33. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.
Falagas ME; Bliziotis IA; Kasiakou SK; Samonis G; Athanassopoulou P; Michalopoulos A
BMC Infect Dis; 2005 Apr; 5():24. PubMed ID: 15819983
[TBL] [Abstract][Full Text] [Related]
34. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.
Moskowitz SM; Ernst RK; Miller SI
J Bacteriol; 2004 Jan; 186(2):575-9. PubMed ID: 14702327
[TBL] [Abstract][Full Text] [Related]
35. Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics.
Armstrong D; Bell S; Robinson M; Bye P; Rose B; Harbour C; Lee C; Service H; Nissen M; Syrmis M; Wainwright C
J Clin Microbiol; 2003 May; 41(5):2266-7. PubMed ID: 12734299
[No Abstract] [Full Text] [Related]
36. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.
Denton M; Kerr K; Mooney L; Keer V; Rajgopal A; Brownlee K; Arundel P; Conway S
Pediatr Pulmonol; 2002 Oct; 34(4):257-61. PubMed ID: 12205566
[TBL] [Abstract][Full Text] [Related]
37. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
[TBL] [Abstract][Full Text] [Related]
38. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
39. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
[TBL] [Abstract][Full Text] [Related]
40. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
Obritsch MD; Fish DN; MacLaren R; Jung R
Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
